144 related articles for article (PubMed ID: 18025280)
1. Bevacizumab and rapamycin inhibit tumor growth in peritoneal model of human ovarian cancer.
Huynh H; Teo CC; Soo KC
Mol Cancer Ther; 2007 Nov; 6(11):2959-66. PubMed ID: 18025280
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma.
Huynh H; Chow PK; Palanisamy N; Salto-Tellez M; Goh BC; Lee CK; Somani A; Lee HS; Kalpana R; Yu K; Tan PH; Wu J; Soong R; Lee MH; Hor H; Soo KC; Toh HC; Tan P
J Hepatol; 2008 Jul; 49(1):52-60. PubMed ID: 18490075
[TBL] [Abstract][Full Text] [Related]
3. Effective inhibition of xenografts of hepatocellular carcinoma (HepG2) by rapamycin and bevacizumab in an intrahepatic model.
Ong LC; Song IC; Jin Y; Kee IH; Siew E; Yu S; Thng CH; Huynh H; Chow PK
Mol Imaging Biol; 2009; 11(5):334-42. PubMed ID: 19330383
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab plus 5-fluorouracil induce growth suppression in the CWR-22 and CWR-22R prostate cancer xenografts.
Hung H
Mol Cancer Ther; 2007 Aug; 6(8):2149-57. PubMed ID: 17699714
[TBL] [Abstract][Full Text] [Related]
5. AAV-mediated persistent bevacizumab therapy suppresses tumor growth of ovarian cancer.
Xie Y; Hicks MJ; Kaminsky SM; Moore MA; Crystal RG; Rafii A
Gynecol Oncol; 2014 Nov; 135(2):325-32. PubMed ID: 25108232
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia-inducible factor 1alpha (HIF-1alpha) correlated with tumor growth and apoptosis in ovarian cancer.
Jiang H; Feng Y
Int J Gynecol Cancer; 2006; 16 Suppl 1():405-12. PubMed ID: 16515634
[TBL] [Abstract][Full Text] [Related]
7. Effect of bevacizumab, a humanized monoclonal antibody to vascular endothelial growth factor, on peritoneal metastasis of MNK-45P human gastric cancer in mice.
Ninomiya S; Inomata M; Tajima M; Ali AT; Ueda Y; Shiraishi N; Kitano S
J Surg Res; 2009 Jun; 154(2):196-202. PubMed ID: 19329124
[TBL] [Abstract][Full Text] [Related]
8. Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model.
Mabuchi S; Terai Y; Morishige K; Tanabe-Kimura A; Sasaki H; Kanemura M; Tsunetoh S; Tanaka Y; Sakata M; Burger RA; Kimura T; Ohmichi M
Clin Cancer Res; 2008 Dec; 14(23):7781-9. PubMed ID: 19047105
[TBL] [Abstract][Full Text] [Related]
9. RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer.
Mabuchi S; Altomare DA; Connolly DC; Klein-Szanto A; Litwin S; Hoelzle MK; Hensley HH; Hamilton TC; Testa JR
Cancer Res; 2007 Mar; 67(6):2408-13. PubMed ID: 17363557
[TBL] [Abstract][Full Text] [Related]
10. Suppressive effect of bevacizumab on peritoneal dissemination from gastric cancer in a peritoneal metastasis model.
Imaizumi T; Aoyagi K; Miyagi M; Shirouzu K
Surg Today; 2010 Sep; 40(9):851-7. PubMed ID: 20740349
[TBL] [Abstract][Full Text] [Related]
11. Biodistribution of humanized anti-VEGF monoclonal antibody/bevacizumab on peritoneal metastatic models with subcutaneous xenograft of gastric cancer in mice.
Yagi Y; Fushida S; Harada S; Tsukada T; Kinoshita J; Oyama K; Fujita H; Ninomiya I; Fujimura T; Kayahara M; Kinuya S; Yashiro M; Hirakawa K; Ohta T
Cancer Chemother Pharmacol; 2010 Sep; 66(4):745-53. PubMed ID: 20033809
[TBL] [Abstract][Full Text] [Related]
12. PEGylated liposome IHL-305 markedly improved the survival of ovarian cancer peritoneal metastasis in mouse.
Konishi H; Takagi A; Kurita A; Kaneda N; Matsuzaki T
BMC Cancer; 2012 Oct; 12():462. PubMed ID: 23046546
[TBL] [Abstract][Full Text] [Related]
13. Crosstalk between PI3K and Ras pathways via protein phosphatase 2A in human ovarian clear cell carcinoma.
Takai M; Nakagawa T; Tanabe A; Terai Y; Ohmichi M; Asahi M
Cancer Biol Ther; 2015; 16(2):325-35. PubMed ID: 25756515
[TBL] [Abstract][Full Text] [Related]
14. The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer.
Inglis DJ; Lavranos TC; Beaumont DM; Leske AF; Brown CK; Hall AJ; Kremmidiotis G
Cancer Biol Ther; 2014; 15(11):1552-60. PubMed ID: 25482941
[TBL] [Abstract][Full Text] [Related]
15. Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model.
Lang SA; Gaumann A; Koehl GE; Seidel U; Bataille F; Klein D; Ellis LM; Bolder U; Hofstaedter F; Schlitt HJ; Geissler EK; Stoeltzing O
Int J Cancer; 2007 Apr; 120(8):1803-10. PubMed ID: 17230506
[TBL] [Abstract][Full Text] [Related]
16. Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy.
Manenti L; Riccardi E; Marchini S; Naumova E; Floriani I; Garofalo A; Dossi R; Marrazzo E; Ribatti D; Scanziani E; Bani M; Belotti D; Broggini M; Giavazzi R
Mol Cancer Ther; 2005 May; 4(5):715-25. PubMed ID: 15897235
[TBL] [Abstract][Full Text] [Related]
17. Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration.
Fan F; Samuel S; Gaur P; Lu J; Dallas NA; Xia L; Bose D; Ramachandran V; Ellis LM
Br J Cancer; 2011 Apr; 104(8):1270-7. PubMed ID: 21407219
[TBL] [Abstract][Full Text] [Related]
18. Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2.
Molhoek KR; Griesemann H; Shu J; Gershenwald JE; Brautigan DL; Slingluff CL
Cancer Res; 2008 Jun; 68(11):4392-7. PubMed ID: 18519701
[TBL] [Abstract][Full Text] [Related]
19. A genetically defined mouse ovarian carcinoma model for the molecular characterization of pathway-targeted therapy and tumor resistance.
Xing D; Orsulic S
Proc Natl Acad Sci U S A; 2005 May; 102(19):6936-41. PubMed ID: 15860581
[TBL] [Abstract][Full Text] [Related]
20. Efficient inhibition of intra-peritoneal tumor growth and dissemination of human ovarian carcinoma cells in nude mice by anti-L1-cell adhesion molecule monoclonal antibody treatment.
Arlt MJ; Novak-Hofer I; Gast D; Gschwend V; Moldenhauer G; Grünberg J; Honer M; Schubiger PA; Altevogt P; Krüger A
Cancer Res; 2006 Jan; 66(2):936-43. PubMed ID: 16424028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
